Semi-Solid Dosage CDMO Market Report Scope & Overview:
The semi-solid dosage CDMO market size was valued at USD 34.42 billion in 2024 and is expected to reach USD 85.19 billion by 2032, growing at a CAGR of 12.02% over the forecast period of 2025-2032.
The global semi-solid dosage CDMO market is mainly driven by cost advantage, research and development outsourcing trends in pharma and biotech industries to access specialized expertise in the field, and the ability to expand production with minimal capital investment. The market further benefits over the migration towards advanced complex formulations encompassing multi-drug, nano-based, and enhanced penetration systems, which necessitate technologies to manufacture, including continuous manufacturing.
For instance, in October 2024, Informa Pharma Intelligence reported an 11% YoY growth in complex semi-solid formulations, with nano-based creams and transdermal patches showing the fastest market expansion.
Key Semi-Solid Dosage CDMO Market Trends
-
Expansion into complex formulations: Increasing development of advanced semi-solid dosage forms, including gels, creams, ointments, and transdermal systems for niche therapeutic areas like dermatology and chronic care.
-
Use of innovative excipients and formulation technologies: Adoption of novel polymers, penetration enhancers, and rheology modifiers to improve stability, bioavailability, and patient compliance.
-
Integration of AI and computational tools: Employing predictive modeling, high-throughput formulation screening, and in silico stability testing to accelerate product development timelines and optimize formulations.
-
Focus on personalized and patient-centric therapies: Development of tailored semi-solid formulations considering patient-specific needs, including pediatric, geriatric, or dermatological sensitivities.
-
Collaborations across pharma, biotech, and CDMOs: Strategic partnerships for co-development, licensing, technology transfer, and large-scale manufacturing to enhance market reach and regulatory compliance.
-
Adoption of novel delivery platforms: Exploration of advanced semi-solid platforms like nanoparticle-loaded creams, hydrogel-based topical systems, and sustained-release ointments to improve efficacy and convenience.
-
Growing pipeline, regulatory support, and market confidence: Increasing semi-solid product launches supported by robust clinical trials, improved regulatory frameworks, and stronger confidence in CDMO capabilities.
Semi-Solid Dosage CDMO Market Report Highlights
The U.S. semi-solid dosage CDMO market was valued at USD 12.09 billion in 2024 and is expected to reach USD 29.53 billion by 2032, growing at a CAGR of 11.83% over 2025-2032. The U.S. leads in the semi-solid dosage CDMO market owing to a large number of pharmaceutical players, advanced R&D infrastructure, and higher outsourcing adoption. Besides, there are several FDA-approved semi-solid manufacturers in the country, which results in high realization of global regulatory compliance. In the US, demand for dermatology, pain management, and transdermal therapies is likely to remain robust, coupled with high generic drug penetration and strong biotech funding, making it the favored destination for innovation and large-scale semi-solid manufacturing partnerships prevalent in other regions.
Semi-Solid Dosage CDMO Market Growth Drivers:
-
Pharma & Biotech Outsourcing Trend is Driving the Semi-Solid Dosage CDMO Market Growth
The rising pharma and biotech outsourcing trend is the chief factor driving the global semi-solid dosage CDMO market share, as companies seek to slash operational costs, avoid investment in infrastructure, and tap into specialized formulation expertise. The semi-solid dosage CDMO market trends in Large and mid-tier drug makers are partnering with semi-solid dosage CDMOs to secure GMP compliance, scale up faster, and be ready for global regulatory inspection.
For instance, in September 2024, PhRMA found 78% of mid-to-large pharma firms outsourced semi-solid production, reflecting a rising Semi-Solid Dosage CDMO Market trend.
Semi-Solid Dosage CDMO Market Restraints:
-
Formulation Stability Challenges are Hampering the Semi-Solid Dosage CDMO Market Growth
Formulation stability challenges hold back the semi-solid dosage CDMO market analysis, as creams, gels, and ointments are prone to physical separation, viscosity changes, and degradation of active ingredients. This causes marketing complications, reduces shelf life, and lengthens the research and development timeline, often requiring reformulation, advanced excipients, or specialty packaging, which can increase cost pressure and program delays in launching a product.
Semi-Solid Dosage CDMO Market Opportunities:
-
Specialized And Personalized Formulations Drive Future Growth Opportunities for the Semi-Solid Dosage CDMO Market
The potential is provided for customized treatments relevant to the proteomic and genetic backgrounds of individual patients through TPD-based therapeutics. Through targeting the proteins that truly drive disease, TPD can offer highly selective interventions, cut off-target damage, and deliver better treatments. These individualised strategies could facilitate precision medicine in cancer, neurodegenerative, and autoimmune diseases, and lead to improved patient response and safety.
For instance, in June 2024, 32% of semi-solid products under development targeted pediatric and geriatric patients, highlighting growth in personalized formulations for specific age and sensitivity needs.
Key Semi-Solid Dosage CDMO Market Segment Analysis
-
By product, creams and lotions held the largest share of around 42.87%in 2024, and the ointments segment is expected to register the highest growth with a CAGR of 12.70%.
-
By route of administration, the topical segment dominated the market with approximately 85.53% share in 2024, while transdermal is expected to register the highest growth with a CAGR of 12.97%.
-
By service, contract manufacturing accounted for the leading share of nearly 69.92% in 2024, while contract development is expected to register the highest growth with a CAGR of 12.40%.
-
By end user, the pharmaceutical companies segment led the market with about 42.80% share in 2024, while the biopharmaceutical companies segment is forecasted to grow the fastest at a CAGR of 12.84%.
By Product, Creams and Lotions Lead the Market, While Ointments Register Fastest Growth
The creams and lotions segment accounted for the highest revenue share of approximately 42.87% in 2024, as they have been extensively used in dermatology, cosmetics, and therapeutics due to providing patient-friendly non-invasive deliveries. Large-scale outsourcing, driven by high demand for OTC skincare, prescription dermatology treatments, and cosmetic cosmeceuticals. In comparison, the ointments segment is anticipated to achieve the highest CAGR of nearly 12.70% during the 2025–2032 period, driven by their predominantly occlusive properties, which are well-suited to chronically compromised skin and wound care, and for drug delivery with extended skin exposure.
By Route of Administration, the Topical Segment dominates, while the Transdermal Segment Shows Rapid Growth
The topical segment held the largest revenue share of approximately 85.53% in 2024, due to extensive use in dermatology, pain management, and cosmetic applications, and patient demand for localized non-invasive treatments. Increased OTC skincare, prescription dermatology drugs, and advanced transdermal delivery systems demand drives the outsourcing trends. On the other hand, the transdermal segment is predicted to grow at the strongest CAGR of approximately 12.97% during 2025–2032, as it slowly releases the drug into the body and can help adherence to therapy while reducing systemic effects of a drug.
By Service, Contract Manufacturing Segment Lead, While Contract Development Registers Fastest Growth
The contract manufacturing segment accounted for the largest share of the Semi-Solid Dosage CDMO Market with about 69.92%, owing to pharmaceutical and biotech companies turning to third-party firms for manufacturing services in order to lower operational expenses, reduce the need for building new facilities, and tap into specialized formulation technology. In addition, the contract development segment is slated to grow at the fastest rate with a CAGR of around 12.40% throughout the forecast period of 2025–2032, as more traditional formulation expertise, stability optimization, and cutting-edge drug delivery innovation all demand specialized focus. Demand for Pharma & biotech to partner with CDMOs for complete end-to-end R&D.
By End User, Pharmaceutical Companies Segment Lead, While the Biopharmaceutical Companies Segment Grows the Fastest
The pharmaceutical companies segment held the largest revenue share of around 42.80% in the Semi-Solid Dosage CDMO Market in 2024, with their broad-based product pipelines in dermatology, pain management, and transdermal therapies that create high-volume outsourcing requirements. They need to save costs and time-to-market while adhering to the strict FDA and EMA guidelines & regulations. On the flip side, the biopharmaceutical companies segment, however, is projected to register the highest CAGR of around 12.84% during the forecast period of 2025 - 2032, as they specialize in advanced drug delivery, including biologic-embedded topicals and transdermal patches. Intensified CDMO outsourcing in specialized R&D and manufacturing competencies creates exigency and brings sustenance to the competitive intermediate phase.
Asia Pacific Semi-Solid Dosage CDMO Market Insights
Asia-Pacific is the fastest-growing segment in the semi-solid dosage CDMO market with a CAGR of 12.91%, driven by burgeoning pharmaceutical industry growth, improved outsourcing over global drug makers, and competitive costs of production. Countries including India, China, and South Korea are spending a lot on GMP-certified semi-solid manufacturing facilities, which is attracting local and foreign clients to these regions. The occurrence of dermatological disorders on a global level, the extension of generic drug markets, and the increased adoption of OTC skincare & therapeutic products by the rising middle-class will continue to boost sales. A combination of government incentives, ready availability of skilled labour, and innovation in formulation technologies, including nano-based delivery systems and enhanced penetration systems, is further contributing to the capability building in the region.
North America Semi-Solid Dosage CDMO Market Insights
North America accounted for the highest revenue share of approximately 41.72% in 2024 of the Semi-Solid Dosage CDMO Market, owing to the presence of a robust pharmaceutical and biotech ecosystem, extensive outsourcing uptake, and numerous FDA-approved manufacturing plants. Other positives are its strong and well-developed R&D infrastructure, heavy investment in dermatology and transdermal therapies, and excellent generic penetration. With lenient regulatory norms, robust intellectual property protection, and increasing consumer demand for OTC and prescription semi-solid products in bulk quantities, North America continues to remain at the top of the table on account of enhanced prevalence of innovation-led large-scale semi-solid contract manufacturing deals.
Europe Semi-Solid Dosage CDMO Market Insights
Europe is holding the second-largest market share of the semi-solid dosage CDMO market due to its well-established pharmaceutical manufacturing base, the presence of GMP-certified facilities, and the high prevalence rate of dermatological diseases and expertise in dermatology and transdermal drug delivery. Strength of the market is buoyed by the combination of advantageous regulation alignment across the EU, high demand in branded and generic semi-solids, and increasing use of CDMOs by domestic and international pharma companies to support innovation, with Germany, France, Italy, and the UK home to some bio/pharma-focused CDMOs relevant for small MedTech firms.
Latin America (LATAM) and Middle East & Africa (MEA) Semi-Solid Dosage CDMO Market Insights
Latin America and the Middle East & Africa (MEA) are evolving as potential growth regions of the semi-solid dosage CDMO market. The increasing incidence of dermatological and chronic diseases, along with growing regulatory guidelines and outsourcing of pharmaceutical services, is driving demand. Brazil, Mexico, the UAE and Saudi Arabia lead in terms of contract activity. CDMOs are using these areas for economical manufacturing and to grow in the market and reach underserved patients.
Competitive Landscape for the Semi-Solid Dosage CDMO Market:
Recipharm is a leading global CDMO specializing in semi-solid and oral dosage forms, offering end-to-end development, manufacturing, and regulatory support, with strong presence in Europe and North America.
-
In March 2025, Recipharm expanded its semi-solid manufacturing capacity in Germany, adding advanced gel and cream production lines to support growing dermatology and chronic care demand.
Thermo Fisher provides integrated contract development and manufacturing services, leveraging advanced technologies, formulation expertise, and regulatory compliance to support pharmaceutical clients in semi-solid and other dosage forms globally.
-
In August 2024, Thermo Fisher launched a new semi-solid formulation development platform in the US, integrating AI-driven predictive modeling to accelerate product optimization and reduce time-to-market.
Aenova is a major CDMO delivering high-quality semi-solid products, including creams, ointments, and gels, with capabilities in formulation development, manufacturing, and packaging, serving global pharmaceutical and consumer health markets.
-
In November 2024, Aenova partnered with a European biotech firm to co-develop sustained-release semi-solid formulations, focusing on nanoparticle and hydrogel delivery systems for patient-centric therapies.
Semi-Solid Dosage CDMO Market Key Players:
Some of the medical suction device market companies are:
-
Recipharm
-
Thermo Fisher Scientific
-
Aenova Group
-
Fareva
-
Famar
-
Delpharm
-
NextPharma
-
Cambrex
-
LTS Lohmann Therapie-Systeme
-
Kindeva Drug Delivery
-
Lubrizol Life Science Health
-
Evonik Health Care
-
MedPharm
-
Tergus Pharma
-
SGS Quay Pharma
-
UPM Pharmaceuticals
-
Aphena Pharma Solutions
-
CoreRx
-
Tiofarma
-
Perrigo
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 34.42 billion |
| Market Size by 2032 | USD 85.19 billion |
| CAGR | CAGR of 12.02% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Ointments, Creams and Lotions, Pastes, Gels, Others) • By Route of Administration (Topical, Transdermal, Others) • By Service (Contract Development, Contract Manufacturing) • By End User (Pharmaceutical Companies, Biopharmaceutical Companies, Others) |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, France, UK, Italy, Spain, Poland, Russsia, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia,ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, Egypt, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia Rest of Latin America) |
| Company Profiles | Recipharm, Thermo Fisher Scientific, Aenova Group, Fareva, Famar, Delpharm, NextPharma, Cambrex, LTS Lohmann Therapie-Systeme, Kindeva Drug Delivery, Lubrizol Life Science Health, Evonik Health Care, MedPharm, Tergus Pharma, SGS Quay Pharma, UPM Pharmaceuticals, Aphena Pharma Solutions, CoreRx, Tiofarma, Perrigo, and other players. |
Table of Contents:
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032
2.3 Market Size & Forecast, By Segmentation, 2021–2032
2.3.1 Market Size By Product
2.3.2 Market Size By Route of Administration
2.3.2 Market Size By Service
2.3.2 Market Size By End User
2.4 Market Share & Bps Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Production Capacity and Volume Trends (2020–2032)
4.1.1 Global and regional semi-solid dosage production volumes
4.1.2 Capacity utilization rates across small, mid-sized, and large CDMOs
4.1.3 Growth rate comparison: topical vs transdermal vs suppository formulations
4.2 Client Segmentation and Demand Drivers (2024)
4.2.1 Distribution of clients by pharma size: big pharma, mid-tier, emerging biotech
4.2.2 Therapeutic area demand trends: dermatology, pain management, hormone therapy, etc.
4.2.3 Regional sourcing preferences and outsourcing penetration rates
4.3 CDMO Ownership, Facility, and Technology Trends (2020–2024)
4.3.1 Distribution of CDMOs by ownership: independent, pharma-owned, PE-backed
4.3.2 Number of new semi-solid manufacturing facilities launched annually by region
4.3.3 Adoption rates of advanced technologies (continuous manufacturing, automated filling, PAT systems)
4.4 Regulatory Compliance and Quality Metrics (2024)
4.4.1 Share of facilities with US FDA, EMA, PMDA, and WHO GMP certifications
4.4.2 Audit pass rates and common regulatory inspection findings
4.4.3 Adoption of data integrity and digital QMS systems
4.5 Cost Structures and Pricing Models (2024)
4.5.1 Average cost per batch for key semi-solid dosage forms by region
4.5.2 Comparison of fee-for-service vs full-service CDMO pricing models
4.5.3 Trends in long-term capacity reservation agreements and cost-plus contracts
5. Semi-Solid Dosage CDMO Market Segmental Analysis & Forecast, By Product, 2021 – 2032, Value (USD Billion)
5.1 Introduction
5.2 Ointments
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.3 Creams and Lotions
5.3.1 Key Trends
5.3.2 Market Size & Forecast, 2021 – 2032
5.4 Pastes
5.4.1 Key Trends
5.4.2 Market Size & Forecast, 2021 – 2032
5.5 Gels
5.5.1 Key Trends
5.5.2 Market Size & Forecast, 2021 – 2032
5.6 Others
5.6.1 Key Trends
5.6.2 Market Size & Forecast, 2021 – 2032
6. Semi-Solid Dosage CDMO Market Segmental Analysis & Forecast, By Route of Administration, 2021 – 2032, Value (USD Billion)
6.1 Introduction
6.2 Topical
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2021 – 2032
6.3 Transdermal
6.3.1 Key Trends
6.3.2 Market Size & Forecast, 2021 – 2032
6.4 Others
6.4.1 Key Trends
6.4.2 Market Size & Forecast, 2021 – 2032
7. Semi-Solid Dosage CDMO Market Segmental Analysis & Forecast, By Service, 2021 – 2032, Value (USD Billion)
7.1 Introduction
7.2 Contract Development
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2021 – 2032
7.3 Contract Manufacturing
7.3.1 Key Trends
7.3.2 Market Size & Forecast, 2021 – 2032
8. Semi-Solid Dosage CDMO Market Segmental Analysis & Forecast, By End User, 2021 – 2032, Value (USD Billion)
8.1 Introduction
8.2 Pharmaceutical Companies
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2021 – 2032
8.3 Biopharmaceutical Companies
8.3.1 Key Trends
8.3.2 Market Size & Forecast, 2021 – 2032
8.4 Others
8.4.1 Key Trends
8.4.2 Market Size & Forecast, 2021 – 2032
9. Semi-Solid Dosage CDMO Market Segmental Analysis & Forecast By Region, 2021 – 2025, Value (USD Billion)
9.1 Introduction
9.2 North America
9.2.1 Key Trends
9.2.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.2.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.2.4 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.2.5 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.2.6 Semi-Solid Dosage CDMO Market Size & Forecast, By Country, 2021 – 2032
9.2.6.1 USA
9.2.6.1.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.2.6.1.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.2.6.1.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.2.6.1.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.2.6.2 Canada
9.2.6.2.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.2.6.2.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.2.6.2.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.2.6.2.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.3 Europe
9.3.1 Key Trends
9.3.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.3.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.4 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.3.5 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.3.6 Semi-Solid Dosage CDMO Market Size & Forecast, By Country, 2021 – 2032
9.3.6.1 Germany
9.3.6.1.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.3.6.1.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.6.1.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.3.6.1.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.3.6.2 UK
9.3.6.2.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.3.6.2.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.6.2.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.3.6.2.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.3.6.3 France
9.3.6.3.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.3.6.3.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.6.3.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.3.6.3.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.3.6.4 Italy
9.3.6.4.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.3.6.4.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.6.4.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.3.6.4.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.3.6.5 Spain
9.3.6.5.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.3.6.5.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.6.5.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.3.6.5.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.3.6.6 Russia
9.3.6.6.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.3.6.6.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.6.6.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.3.6.6.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.3.6.7 Poland
9.3.6.7.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.3.6.7.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.6.7.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.3.6.7.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.3.6.8 Rest of Europe
9.3.6.8.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.3.6.8.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.3.6.8.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.3.6.8.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.4 Asia-Pacific
9.4.1 Key Trends
9.4.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.4.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.4.4 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.4.5 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.4.6 Semi-Solid Dosage CDMO Market Size & Forecast, By Country, 2021 – 2032
9.4.6.1 China
9.4.6.1.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.4.6.1.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.4.6.1.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.4.6.1.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.4.6.2 India
9.4.6.2.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.4.6.2.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.4.6.2.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.4.6.2.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.4.6.3 Japan
9.4.6.3.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.4.6.3.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.4.6.3.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.4.6.3.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.4.6.4 South Korea
9.4.6.4.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.4.6.4.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.4.6.4.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.4.6.4.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.4.6.5 Australia
9.4.6.5.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.4.6.5.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.4.6.5.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.4.6.5.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.4.6.6 ASEAN Countries
9.4.6.6.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.4.6.6.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.4.6.6.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.4.6.6.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.4.6.7 Rest of Asia-Pacific
9.4.6.7.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.4.6.7.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.4.6.7.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.4.6.7.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.5 Latin America
9.5.1 Key Trends
9.5.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.5.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.5.4 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.5.5 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.5.6 Semi-Solid Dosage CDMO Market Size & Forecast, By Country, 2021 – 2032
9.5.6.1 Brazil
9.5.6.1.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.5.6.1.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.5.6.1.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.5.6.1.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.5.6.2 Argentina
9.5.6.2.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.5.6.2.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.5.6.2.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.5.6.2.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.5.6.3 Mexico
9.5.6.3.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.5.6.3.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.5.6.3.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.5.6.3.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.5.6.4 Colombia
9.5.6.4.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.5.6.4.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.5.6.4.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.5.6.4.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.5.6.5 Rest of Latin America
9.5.6.5.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.5.6.5.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.5.6.5.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.5.6.5.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.6 Middle East & Africa
9.6.1 Key Trends
9.6.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.6.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.6.4 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.6.5 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.6.6 Semi-Solid Dosage CDMO Market Size & Forecast, By Country, 2021 – 2032
9.6.6.1 UAE
9.6.6.1.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.6.6.1.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.6.6.1.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.6.6.1.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.6.6.2 Saudi Arabia
9.6.6.2.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.6.6.2.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.6.6.2.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.6.6.2.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.6.6.3 Qatar
9.6.6.3.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.6.6.3.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.6.6.3.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.6.6.3.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.6.6.4 Egypt
9.6.6.4.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.6.6.4.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.6.6.4.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.6.6.4.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.6.6.5 South Africa
9.6.6.5.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.6.6.5.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.6.6.5.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.6.6.5.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
9.6.6.6 Rest of Middle East & Africa
9.6.6.6.1 Semi-Solid Dosage CDMO Market Size & Forecast, By Product, 2021 – 2032
9.6.6.6.2 Semi-Solid Dosage CDMO Market Size & Forecast, By Route of Administration, 2021 – 2032
9.6.6.6.3 Semi-Solid Dosage CDMO Market Size & Forecast, By Service, 2021 – 2032
9.6.6.6.4 Semi-Solid Dosage CDMO Market Size & Forecast, By End User, 2021 – 2032
10. Competitive Landscape
10.1 Key Players' Positioning
10.2 Competitive Developments
10.2.1 Key Strategies Adopted (%), By Key Players, 2024
10.2.2 Year-Wise Strategies & Development, 2021 – 2025
10.2.3 Number Of Strategies Adopted By Key Players, 2024
10.3 Market Share Analysis, 2024
10.4 Product/Service & Application Benchmarking
10.4.1 Product/Service Specifications & Features By Key Players
10.4.2 Product/Service Heatmap By Key Players
10.4.3 Application Heatmap By Key Players
10.5 Industry Start-Up & Innovation Landscape
10.6 Key Company Profiles
10.6 Key Company Profiles
10.6.1 Recipharm
10.6.1.1 Company Overview & Snapshot
10.6.1.2 Product/Service Portfolio
10.6.1.3 Key Company Financials
10.6.1.4 SWOT Analysis
10.6.2 Thermo Fisher Scientific
10.6.2.1 Company Overview & Snapshot
10.6.2.2 Product/Service Portfolio
10.6.2.3 Key Company Financials
10.6.2.4 SWOT Analysis
10.6.3 Aenova Group
10.6.3.1 Company Overview & Snapshot
10.6.3.2 Product/Service Portfolio
10.6.3.3 Key Company Financials
10.6.3.4 SWOT Analysis
10.6.4 Fareva
10.6.4.1 Company Overview & Snapshot
10.6.4.2 Product/Service Portfolio
10.6.4.3 Key Company Financials
10.6.4.4 SWOT Analysis
10.6.5 Famar
10.6.5.1 Company Overview & Snapshot
10.6.5.2 Product/Service Portfolio
10.6.5.3 Key Company Financials
10.6.5.4 SWOT Analysis
10.6.6 Delpharm
10.6.6.1 Company Overview & Snapshot
10.6.6.2 Product/Service Portfolio
10.6.6.3 Key Company Financials
10.6.6.4 SWOT Analysis
10.6.7 NextPharma
10.6.7.1 Company Overview & Snapshot
10.6.7.2 Product/Service Portfolio
10.6.7.3 Key Company Financials
10.6.7.4 SWOT Analysis
10.6.8 Cambrex
10.6.8.1 Company Overview & Snapshot
10.6.8.2 Product/Service Portfolio
10.6.8.3 Key Company Financials
10.6.8.4 SWOT Analysis
10.6.9 LTS Lohmann Therapie-Systeme
10.6.9.1 Company Overview & Snapshot
10.6.9.2 Product/Service Portfolio
10.6.9.3 Key Company Financials
10.6.9.4 SWOT Analysis
10.6.10 Kindeva Drug Delivery
10.6.10.1 Company Overview & Snapshot
10.6.10.2 Product/Service Portfolio
10.6.10.3 Key Company Financials
10.6.10.4 SWOT Analysis
10.6.11 Lubrizol Life Science Health
10.6.11.1 Company Overview & Snapshot
10.6.11.2 Product/Service Portfolio
10.6.11.3 Key Company Financials
10.6.11.4 SWOT Analysis
10.6.12 Evonik Health Care
10.6.12.1 Company Overview & Snapshot
10.6.12.2 Product/Service Portfolio
10.6.12.3 Key Company Financials
10.6.12.4 SWOT Analysis
10.6.13 MedPharm
10.6.13.1 Company Overview & Snapshot
10.6.13.2 Product/Service Portfolio
10.6.13.3 Key Company Financials
10.6.13.4 SWOT Analysis
10.6.14 Tergus Pharma
10.6.14.1 Company Overview & Snapshot
10.6.14.2 Product/Service Portfolio
10.6.14.3 Key Company Financials
10.6.14.4 SWOT Analysis
10.6.15 SGS Quay Pharma
10.6.15.1 Company Overview & Snapshot
10.6.15.2 Product/Service Portfolio
10.6.15.3 Key Company Financials
10.6.15.4 SWOT Analysis
10.6.16 UPM Pharmaceuticals
10.6.16.1 Company Overview & Snapshot
10.6.16.2 Product/Service Portfolio
10.6.16.3 Key Company Financials
10.6.16.4 SWOT Analysis
10.6.17 Aphena Pharma Solutions
10.6.17.1 Company Overview & Snapshot
10.6.17.2 Product/Service Portfolio
10.6.17.3 Key Company Financials
10.6.17.4 SWOT Analysis
10.6.18 CoreRx
10.6.18.1 Company Overview & Snapshot
10.6.18.2 Product/Service Portfolio
10.6.18.3 Key Company Financials
10.6.18.4 SWOT Analysis
10.6.19 Tiofarma
10.6.19.1 Company Overview & Snapshot
10.6.19.2 Product/Service Portfolio
10.6.19.3 Key Company Financials
10.6.19.4 SWOT Analysis
10.6.20 Perrigo
10.6.20.1 Company Overview & Snapshot
10.6.20.2 Product/Service Portfolio
10.6.20.3 Key Company Financials
10.6.20.4 SWOT Analysis
11. Analyst Recommendations
11.1 SNS Insider Opportunity Map
11.2 Industry Low-Hanging Fruit Assessment
11.3 Market Entry & Growth Strategy
11.4 Analyst Viewpoint & Suggestions On Market Growth
12. Assumptions
13. Disclaimer
14. Appendix
14.1 List Of Tables
14.2 List Of Figures
Key Segments:
By Product
-
Ointments
-
Creams and Lotions
-
Pastes
-
Gels
-
Others
By Route of Administration
-
Topical
-
Transdermal
-
Others
By Service
-
Contract Development
-
Contract Manufacturing
By End User
-
Pharmaceutical Companies
-
Biopharmaceutical Companies
-
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
ASEAN Countries
-
Australia
-
Rest of Asia Pacific
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
Egypt
-
South Africa
-
Rest of Middle East & Africa
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g., Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
